| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02335aa0f89ac30046472bbf775ef15c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2019-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_105d0eef2e1d1c1e301b8306a72aa26d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2af826d94557bf10801f1ef270d78cca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b64466aba798f536188a9e13d61962f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a06e9a50d24d339b8b4bd1ab4d7c57c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ceb67c16708e11c1a575b35195d98112 |
| publicationDate |
2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019269671-A1 |
| titleOfInvention |
Method for treating tumour, pharmaceutical composition and medicinal kit |
| abstract |
The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11279676-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10888559-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10730878-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736887-B2 |
| priorityDate |
2014-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |